SC 68896

11/01/2009 - "Using RNA interference, we show that the effect of SC68896 on glioma cells is facilitated by wild-type p53. "
11/01/2009 - "An orthotopic human glioma xenograft model in nude mice was used to examine the in vivo activity of SC68896. "
11/01/2009 - "SC68896 inhibits the proliferation of cell lines of different types of cancer, including malignant glioma. "
01/01/2015 - "We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib and the novel proteasome inhibitor SC68896, in combination and as single agents. "
11/01/2009 - "SC68896 sensitizes glioma cells to tumor necrosis factor-related apoptosis-inducing ligand and CD95 ligand and up-regulates the cell surface expression of the tumor necrosis factor-related apoptosis-inducing ligand receptor cell death receptors 4 and 5, which may contribute to this sensitization. "

11/01/2009 - "SC68896 inhibits the proliferation of cell lines of different types of cancer, including malignant glioma. "
01/01/2015 - "While single agent cediranib or SC68896 treatment did not alter tumor growth or survival, combined cediranib/SC68896 significantly delayed tumor growth and increased median survival by 2-fold, compared to untreated. "
01/01/2015 - "This was accompanied by substantially increased tumor necrosis in the cediranib/SC68896 group (p<0.01), not observed with single agent treatments. "

01/01/2015 - "This was accompanied by substantially increased tumor necrosis in the cediranib/SC68896 group (p<0.01), not observed with single agent treatments. "